As for vemurafenib, the efficacy of dabrafenib was further extended when combined with a MEK inhibitor (trametinib)[138,139], which led to approval of dabrafenib plus trametinib, as a combinatorial agent for treating advance melanoma harboring BRAF(V600E/K) mutations in clinical therapy. Here, MAP2K7 is linked to melanoma.